Coral Laboratories Ltd
Incorporated in 1994, Coral Laboratories Ltd is in the business of pharmaceutical formulations[1]
- Market Cap ₹ 169 Cr.
- Current Price ₹ 473
- High / Low ₹ 999 / 470
- Stock P/E 9.15
- Book Value ₹ 563
- Dividend Yield 0.42 %
- ROCE 17.4 %
- ROE 13.1 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.84 times its book value
- Company has delivered good profit growth of 28.2% CAGR over last 5 years
Cons
- Company has a low return on equity of 9.21% over last 3 years.
- Earnings include an other income of Rs.8.82 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
51 | 59 | 77 | 95 | 92 | 91 | 71 | 97 | 76 | 78 | 84 | 115 | 102 | |
41 | 47 | 60 | 72 | 77 | 79 | 65 | 81 | 67 | 74 | 67 | 89 | 84 | |
Operating Profit | 10 | 12 | 16 | 23 | 15 | 12 | 5 | 16 | 8 | 4 | 16 | 26 | 18 |
OPM % | 20% | 21% | 21% | 24% | 17% | 14% | 8% | 16% | 11% | 5% | 19% | 23% | 17% |
1 | 3 | 3 | 3 | 4 | 5 | 6 | 4 | 6 | 7 | 6 | 8 | 9 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Profit before tax | 10 | 12 | 17 | 25 | 18 | 16 | 9 | 18 | 12 | 8 | 21 | 32 | 24 |
Tax % | 21% | 22% | 29% | 34% | 31% | 34% | 22% | 23% | 24% | 22% | 24% | 26% | |
8 | 10 | 12 | 16 | 12 | 10 | 7 | 14 | 9 | 6 | 16 | 24 | 18 | |
EPS in Rs | 22.03 | 26.79 | 34.71 | 45.63 | 34.85 | 28.61 | 19.96 | 37.93 | 25.33 | 18.05 | 44.20 | 67.63 | 50.14 |
Dividend Payout % | 9% | 9% | 9% | 11% | 6% | 7% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 10% |
3 Years: | 15% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 28% |
3 Years: | 44% |
TTM: | -19% |
Stock Price CAGR | |
---|---|
10 Years: | -1% |
5 Years: | 11% |
3 Years: | 23% |
1 Year: | -48% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 9% |
3 Years: | 9% |
Last Year: | 13% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Reserves | 47 | 56 | 67 | 106 | 113 | 110 | 112 | 133 | 152 | 151 | 174 | 198 |
0 | 1 | 0 | 2 | 2 | 1 | 6 | 6 | 6 | 0 | 0 | 4 | |
10 | 12 | 19 | 20 | 22 | 21 | 23 | 25 | 28 | 20 | 28 | 25 | |
Total Liabilities | 60 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 |
20 | 19 | 18 | 18 | 22 | 23 | 23 | 21 | 24 | 25 | 24 | 23 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
Investments | 1 | 1 | 5 | 39 | 45 | 28 | 25 | 33 | 46 | 41 | 50 | 52 |
40 | 52 | 67 | 74 | 73 | 84 | 97 | 112 | 118 | 108 | 132 | 152 | |
Total Assets | 60 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 0 | 5 | 11 | 13 | -1 | -4 | 1 | 6 | 13 | -5 | -1 | |
1 | -0 | -3 | -10 | -13 | 3 | -2 | -0 | -6 | -3 | 1 | -0 | |
0 | -0 | -0 | 0 | -3 | -1 | 4 | 0 | 0 | -6 | 0 | 3 | |
Net Cash Flow | 2 | -0 | 2 | 1 | -2 | 1 | -2 | 1 | 0 | 4 | -4 | 1 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 109 | 152 | 132 | 117 | 125 | 122 | 178 | 148 | 184 | 109 | 123 | 107 |
Inventory Days | 97 | 110 | 110 | 155 | 120 | 116 | 176 | 158 | 169 | 100 | 149 | 68 |
Days Payable | 61 | 66 | 80 | 75 | 87 | 91 | 129 | 108 | 81 | 34 | 130 | 46 |
Cash Conversion Cycle | 145 | 196 | 162 | 197 | 157 | 146 | 225 | 198 | 272 | 176 | 142 | 129 |
Working Capital Days | 158 | 194 | 179 | 164 | 161 | 171 | 241 | 178 | 222 | 221 | 183 | 228 |
ROCE % | 21% | 22% | 27% | 28% | 16% | 13% | 8% | 13% | 7% | 5% | 13% | 17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
13 Aug - Board approved alteration of MoA object clause to expand pharmaceutical and healthcare business scope.
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
13 Aug - Appointment of M/s S C Mehra & Associates as statutory auditor for FY 2025-26 to 2029-30.
- Outcome Of Board Meeting Held On August 13, 2025 13 Aug
-
Board Meeting Outcome for Outcome Of Board Meeting Held On August 13, 2025
13 Aug - Q1 2025 results approved; AGM set for Sept 26; new auditor appointed; MOA object clause altered.
-
Board Meeting Intimation for Under Regulation 29(1) Of SEBI (LODR) Regulations, 2015
8 Aug - Board meeting on Aug 13 to approve Q1 results, AGM date, auditor appointment, and MOA alteration.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
CLL is an ISO 9001:2008 certified manufacturer and exporter of pharmaceutical formulations like tablets, capsules, liquid, and topical preparations. It focuses on generics, troubleshooting existing products, and patent noninfringing products for emerging markets.